STOCK TITAN

Zentek Q2 Fiscal 2027 Results News Release

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Zentek (ZTEKF) ended its fiscal 2027 second quarter with C$13.6 million in cash, following its May financing. At September 30, 2026, working capital was C$11.3 million, versus a C$1.3 million deficit at March 31; cash was C$1.3 million at that earlier date. The financing provided approximately C$16 million in net proceeds.

Quarterly net income of C$17.2 million included a C$19.7 million non-cash reversal of an Albany Graphite Project impairment. Excluding that reversal, the non-IFRS loss was C$2.5 million, about unchanged year over year. Operating expenses rose 7%, while six-month operating cash use increased to C$3.6 million from C$2.4 million. Since the financing closed, Zentek has spent C$1.2 million developing Albany, including completing its preliminary economic assessment. ZenGUARD filters are now selling in Canada and the United States.

Loading...
Loading translation...
9 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 4 points

How the balance works

Positive

  • Major pointMay 2026 financing provided approximately C$16 million in net proceeds.
  • Minor pointCash increased to C$13.6 million at September 30, 2026, from C$1.3 million at March 31, 2026.
  • Minor pointWorking capital reached C$11.3 million at September 30, versus a C$1.3 million deficit at March 31, 2026.
  • Minor pointQuarterly net income of C$17.2 million included a C$19.7 million non-cash Albany impairment reversal.
  • Minor pointSix-month net income was C$15,157,172, including the same Albany impairment reversal.
4 minor points
  • Minor pointTotal assets increased to C$49.4 million at September 30, from C$15.1 million at March 31, 2026.
  • Minor pointAlbany development spending totaled C$1.2 million since financing closed, including a completed preliminary economic assessment.
  • Minor pointZenGUARD filters are now selling in Canada and the United States.
  • Minor pointQuarterly salaries and benefits fell to C$0.5 million from C$1.0 million a year earlier.

Negative

  • Moderate pointSix-month operating cash use increased to C$3.6 million, versus C$2.4 million a year earlier.
  • Moderate pointSix-month loss excluding the impairment reversal was C$4,514,763, a non-IFRS measure.
  • Moderate pointQuarterly operating expenses rose 7% year over year, mainly from higher professional, consulting, share-based compensation and listing costs.
  • Minor pointQuarterly loss excluding the impairment reversal was C$2.5 million, about unchanged year over year, a non-IFRS measure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Zentek Strengthens Its Balance Sheet, Ends Second Quarter with $13.6 Million in Cash

Working capital of $11.3 million at September 30, 2026, compared with a deficit of $1.3 million at March 31, 2026

Guelph, Ontario--(Newsfile Corp. - November 16, 2026) - Zentek Ltd. (TSXV: ZEN) (OTCQX: ZTEKF) ("Zentek" or the "Company") today reported results for the three and six months ended September 30, 2026, the second quarter of its 2027 fiscal year. The quarter reflects the Company's focus this year on putting its finances on a firm footing, so that it can fund the next steps for Albany and ZenGUARD™ from cash on hand.

The unaudited condensed interim consolidated financial statements and MD&A are available under the Company's profiles on SEDAR+ and EDGAR. All amounts are in Canadian dollars unless stated otherwise.

A stronger balance sheet

Cannot view this image? Visit: https://images.newsfilecorp.com/files/1429/324416_59deb1b0341faa23_001.jpg

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/1429/324416_59deb1b0341faa23_001full.jpg

Balance sheet · September 30, 2026 vs. March 31, 2026

Strengthening the balance sheet was a priority this year. At March 31, 2026, Zentek had $1.3 million in cash and a working capital deficit of $1.3 million, which limited what the Company could commit to.

The May 2026 financing, which provided the Company with approximately $16 million in net proceeds, changed that. At September 30, 2026, cash was $13.6 million and working capital was $11.3 million. Total assets were $49.4 million, up from $15.1 million, mainly from the financing and the reversal of the previous impairment of the Albany Graphite Project (discussed below). Cash used in operating activities was $3.6 million for the six months, compared with $2.4 million a year earlier.

The Company put that capital to work. Since the financing closed, Zentek has spent $1.2 million on developing and de-risking the Albany Graphite Project, including completing its preliminary economic assessment ("PEA"). During the quarter, it also recruited new team members to build its commercial capability and its path to revenue.

During the period ended September 30, 2026, the Company assessed whether the impairment loss previously recognized on its Albany Graphite Project remained appropriate. In fiscal 2022, following a shift in the Company's business focus away from mining activities and toward healthcare solutions, the Company recognized an impairment charge of $19.7 million, reducing the carrying amount of the Albany Graphite Project from $26.7 million to $7.0 million. Following the Company's August 10, 2026 announcement of an updated PEA and mineral resource estimate, management concluded that the fair value less costs of disposal ("FVLCD") of the Albany Graphite Project was approximately $45.5 million to $58.5 million, with a midpoint of approximately $52.0 million. Immediately before the impairment reversal, the carrying amount of the Albany Graphite Project was approximately $9.1 million. Although the estimated FVLCD exceeded the carrying amount, the reversal of a previously recognized impairment loss was limited to the carrying amount that would have been determined, net of amortization, had no impairment loss been recognized. Accordingly, the reversal recognized during the three and six months ended September 30, 2026 was limited to approximately $19.7 million, resulting in a carrying amount of approximately $28.8 million at September 30, 2026.

Net income for the quarter was $17.2 million, reflecting the $19.7 million non-cash Albany Graphite Project impairment reversal. Excluding it, the loss was $2.5 million, about the same as a year earlier (see "Non-IFRS measure" below).

Operating expenses rose 7% from a year earlier, mainly from higher professional fees, most of which were one-time costs, consulting fees, share-based compensation and listing fees, partly offset by salaries and benefits, which fell to $0.5 million from $1.0 million.

CEO quote

"2026 has been a year of putting fundamentals in place, and the last quarter was critical to that work. Our science is the foundation of this company. Turning it into a strong Canadian business also takes a defined path for each asset and the balance sheet to fund the next steps. That is where our attention has been this year. We deploy capital with discipline, stay focused on what moves each asset forward and keep the balance sheet efficient, because that is how lasting value is built. We built on the science and the assets this company has assembled over many years, and focused on the work that turns them into businesses: a completed preliminary economic assessment for Albany, ZenGUARD™ filters now selling in Canada and the United States, mask production under our own control, and $13.6 million in cash.

From here, our work is to keep reducing risk and building value, one documented step at a time: filling orders, showing our purification results hold at larger scale, and getting independent test results on our newer materials. We are in this for the mission. That means creating lasting value for our shareholders, for Constance Lake First Nation, our partner at Albany, for our team members, and for Canada. "

Mohammed Jiwan, CEO, Zentek Ltd.

About Zentek

Zentek is an intellectual property development and commercialization company in advanced materials. It is focused on three platforms: specialty materials, including the ZenGUARD™ coating for filters and personal protective equipment; the Albany Graphite Project; and aptamer-based technologies held through its subsidiary, Triera Biosciences Ltd.

The Albany Graphite Project in Northern Ontario is 100% owned by Zentek through Albany Graphite Corp. It hosts igneous-hosted, fluid-derived natural graphite in a gabbro intrusion and breccia pipe vent system.

Non-IFRS measure

"Loss excluding impairment reversal" is net income (loss) less the impairment reversal of exploration and evaluation assets. It has no standardized meaning under IFRS and may not be comparable to similar measures of other issuers. Management uses it to show results from operations without a non-cash, non-recurring item. Reconciliation for the three months ended September 30, 2026: net income of $17,200,847 less the impairment reversal of $19,671,935 equals a loss of $2,471,088. For the six months: net income of $15,157,172 less $19,671,935 equals a loss of $4,514,763. No reversal was recorded in the comparative periods. "Working capital" also has no standardized meaning under IFRS and is calculated as current assets less current liabilities.

Forward-looking statements

This news release contains forward-looking statements, including statements about filling and growing ZenGUARD™ orders, the results and timing of purification, the use of proceeds, and the Albany Graphite Project and its PEA. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risks described under "Risks and Uncertainties" in the Company's MD&A for the period ended September 30, 2026. Bench-scale and preclinical results are not necessarily indicative of results at larger scale or in clinical use. Zentek does not undertake to update forward-looking statements except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact

Mohammed (Moe) Jiwan, CEO

Mjiwan2@zentek.com , 437 567 6146

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324416

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash did Zentek have at the end of fiscal Q2 2027?

Zentek had C$13.6 million in cash at September 30, 2026, compared with C$1.3 million at March 31, 2026. Working capital was C$11.3 million, compared with a C$1.3 million deficit at the earlier date.

Why did Zentek report a profit in fiscal Q2 2027?

Zentek's C$17.2 million quarterly net income reflected a C$19.7 million non-cash reversal of a previous Albany Graphite Project impairment. Excluding the reversal, the quarterly loss was C$2.5 million, about the same as a year earlier. That adjusted loss is a non-IFRS measure.

How did Zentek value Albany for the impairment reversal?

Management estimated Albany's fair value less disposal costs at approximately C$45.5 million to C$58.5 million, following the updated preliminary economic assessment and mineral resource estimate announced August 10, 2026. The reversal was capped at the carrying amount that would have applied without the prior impairment, net of amortization, resulting in a carrying amount of approximately C$28.8 million at September 30, 2026.

Keep reading